8-K/A: GlucoTrack Corrects Error in Share Issuance Related to Series B Warrants

GlucoTrack files an amendment to its previous 8-K report to correct a scrivener's error regarding the number of shares issuable upon exchange of Series B Warrants.

Summary

• GlucoTrack, Inc. filed an amendment to its original Form 8-K report to correct an error related to the aggregate number of shares of common stock that may be issued upon the exchange of the remaining Series B Warrants.
• On November 12, 2024, GlucoTrack commenced a public offering and issued 10,030,145 Series B Warrants.
• From January 6, 2025, through January 13, 2025, the company received exchange notices for 6,950,240 Series B Warrants, requiring the delivery of 134,785,015 shares of common stock.
• The remaining 3,079,905 Series B Warrants are exchangeable for approximately 59,728,158 shares of common stock, subject to standard adjustments.
• The Series B Warrants included a cashless exercise feature, allowing holders to acquire up to 300% of the shares obtainable through a cash exercise.
• The issuance of common stock was exempt from registration under Section 3(a)(9) of the Securities Act of 1933 because the shares were issued in exchange for outstanding securities without additional consideration or commissions.

Sentiment

Score: 6

Explanation: The document is a technical correction, so the sentiment is neutral. It corrects a previous error, which is a positive from a transparency perspective, but doesn't indicate significant positive or negative developments for the company.

Industry Context

This announcement relates to the specific financial instruments and capital structure of GlucoTrack, and doesn't provide broad insights into the medical device industry or its competitors.

Stakeholder Impact

• Shareholders are impacted by the correction of information regarding the number of shares potentially issuable upon warrant exchange.

Key Dates